MTOR and nonpapillary renal cell carcinoma: Moreover, VHL mutation also activates the mammalian target of rapamycin (mTOR) signaling pathway, which in turn upregulates HIF and angiogenesis, subsequently accelerating the progression of ccRCC [9].